In understanding what makes the patient voice so essential to successful drug development, let’s take a critical eye to what ...

The new year is shaping up to be a defining year following a dramatic 2025, and one where the impact from last year's developments will crystallize.

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Traws Pharma, Inc. (TRAW) has disclosed a new risk, in the Corporate Activity and Growth category. The integration of Onconova and Trawsfynydd poses a significant risk to Traws Pharma, Inc.’s future ...

Fierce’s Rebecca Willumson sat down with Swoop President Scott Rines – live at Digital Pharma East – to discuss some of the most pressing issues in pharma marketing today. Rines kicks off by debunking ...

Drug developers integrate AI capabilities as a potentially transformative strategy to combat patent cliff losses.

My initial rating of Abbott Laboratories is a buy, agreeing with today's Wall Street consensus. The future growth indicators, diversified portfolio across many clinical segments, and leading roles in ...

India’s pharmaceutical exports to the US will remain duty-free under a new interim trade deal, providing a major boost to ...

The integration of cannabinoids into mainstream pharmaceutical practices has been a topic of significant debate and interest over the past decade. As scientific research continues to unravel the ...

HANGZHOU, ZHEJIANG, CHINA, January 16, 2026 /EINPresswire.com/ -- The pharmaceutical industry is undergoing a period of ...

Lumos Pharma (NASDAQ:LUMO) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...